Can adding immunotherapy to HER2 therapy erase more tumors?
Disease control
Not yet recruiting
This trial tests whether adding an immunotherapy drug called retifanlimab to two standard HER2-targeted therapies (trastuzumab and pertuzumab) can improve treatment response in people with HER2-positive breast cancer. The main goal is to see if the combination leads to a complete…
Phase 2 • Sponsor: Polly A. Niravath, MD • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC